VPC
APRE icon

Vestal Point Capital’s Aprea Therapeutics APRE Stock Holding History

Vestal Point Capital’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$281K Hold
350,000
– – 0.01% 68
2026
Q1 		$267K Buy
+350,000
New +$275K 0.01% 90

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Vestal Point Capital's APRE Position: Q2 2026 in Review

Vestal Point Capital held its Aprea Therapeutics (APRE) position steady in Q2 2026 at 350,000 shares worth $281K. The position accounts for 0.01% of the portfolio, ranked #68.

Vestal Point Capital first reported a position in APRE in Q1 2026 and has held it in 2 quarters since. 28 funds tracked by Wall St. Rank hold APRE as of Q2 2026.

  • Vestal Point Capital held 350,000 shares of Aprea Therapeutics worth $281K as of Q2 2026.
  • Vestal Point Capital left its Aprea Therapeutics share count unchanged in Q2 2026.
  • Aprea Therapeutics made up 0.01% of Vestal Point Capital's portfolio in Q2 2026, its #68 holding.
  • Vestal Point Capital first reported a position in Aprea Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 28 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.